Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection

BACKGROUND: Boceprevir and telaprevir have recently showed dramatically better treatment outcomes than conventional PEGylated interferon plus ribavirin for the treatment of hepatitis C virus genotype 1, but the average cost per patient is unknown. METHODS: In the UK context, we performed a budget im...

Descripción completa

Detalles Bibliográficos
Autores principales: Thorlund, Kristian, Druyts, Eric, El Khoury, Antoine C, Mills, Edward J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3503472/
https://www.ncbi.nlm.nih.gov/pubmed/23180971
http://dx.doi.org/10.2147/CEOR.S37205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3503472/
https://www.ncbi.nlm.nih.gov/pubmed/23180971
http://dx.doi.org/10.2147/CEOR.S37205

Ejemplares similares